Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

SERUM LncRNA SNHG16: A Biomarker for Diagnosing Childhood Obesity and Predicting Its Progression to Metabolic Syndrome

Hu J., Zheng Z., Liang D., Zhang Y., Chen J., Zhou C.

Prospective Study, published in Diabetes Metab Syndr Obes (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Diabetes Metab Syndr Obes (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40655166
PMCID
PMC12256061
DOI
10.2147/dmso.s513449
Citations
1

Abstract (original English)

Purpose Obesity is a major risk factor for metabolic syndrome (MS) in children. This study explores the expression and clinical significance of long non-coding RNA SNHG16 (SNHG16) in childhood obesity and its complications with MS (obesity-MS). Patients and methods Healthy controls and obese children (categorized as those with simple obesity or obesity-MS) were enrolled. Serum SNHG16 and miR-27a-3p levels were quantified by RT-qPCR. ROC curves evaluated SNHG16's diagnostic value for obesity. Logistic regression analysis identified potential risk factors for the development of obesity-MS. DLR assay and RIP assay confirmed the interaction between SNHG16 and miR-27a-3p. Bioinformatics was used to predict downstream genes of miR-27a-3p and, then GO and KEGG enrichment analysis identified the functions and signaling pathways of these genes. Results Serum SNHG16 levels were distinctly upregulated in obese children, especially those with obesity-MS. In contrast, miR-27a-3p expression showed the opposite trend. Additionally, SNHG16 was positively correlated with BMI in obese children. Serum SNHG16 exhibited 81.18% sensitivity and 76.47% specificity in distinguishing controls from obese individuals. Furthermore, serum SNHG16, BMI, HOMA-IR, and TG are potential risk factors for MS in obese children. Mechanistically, SNHG16 directly targets miR-27a-3p, and miR-27a-3p targets 65 genes prim

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.